OnCore Biopharma Announces Exclusive HBV Research

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute

DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral treatments for chronic hepatitis B virus (HBV) infection, announced today it has entered into a Hepatitis B Virus ("HBV") and liver cancer research collaboration with the Baruch S. Blumberg Institute ("Blumberg"), which is the research center of the Hepatitis B Foundation located in Doylestown, Pennsylvania.

Under the terms of the agreement, OnCore and Blumberg will work collaboratively on projects, based on an overarching research plan, in the HBV and liver cancer fields with funding for projects provided by OnCore. Projects can include identification of new HBV targets, identification and development of new therapeutic compound series, new assay development and other technologies for hepatitis B and liver cancer. In consideration for funding these efforts, Blumberg has granted OnCore the right to obtain royalty-bearing worldwide licenses to Blumberg's rights for inventions made during the term of the agreement. The Company also has the option to increase its funding level to capture additional projects that may fall outside the initial scope of the agreement. The initial agreement is for three years and is renewable at OnCore's option for an additional three years at the same funding level.

"We are excited to be working with OnCore to further our mission of finding a cure for and improving the quality of life for those affected by hepatitis B worldwide," said Dr. Timothy Block, President of the Baruch S. Blumberg Institute. "We have great confidence in the OnCore team, and are aligned with their strategy to deliver an all-oral cure for hepatitis B."

"We are thrilled to establish this research collaboration with the Blumberg Institute, one of the largest repositories of HBV research in the world," stated OnCore's Chief Scientific Officer, Dr. Michael Sofia. "We believe that continuing to invest in novel therapeutic agents, assays and approaches is critical. Blumberg's research is world-class and an exclusive relationship will help further our shared goal of delivering a curative regimen for hepatitis B patients and add to our growing platform of HBV therapeutics."

About Hepatitis B

Hepatitis B is a serious infection of the liver caused by the hepatitis B virus (HBV) and is considered a major global health problem. Hepatitis B infection can cause chronic liver disease, which increases a patient's risk of death from liver cirrhosis and liver cancer. Estimates from the Centers for Disease Control and Prevention (CDC) indicate that up to 350 million people globally may be chronically infected with hepatitis B and, according to the World Health Organization (WHO), more than 780,000 people die every year due to hepatitis B. Most currently-available therapies aim to suppress this viral infection but do not lead to a cure in the overwhelming majority of patients.

About OnCore

We are a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus, or HBV. Our founding management team has significant experience developing and commercializing drug candidates targeting infectious liver diseases, including HCV. Leveraging this experience, we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will ultimately result in a combination therapy to cure hepatitis B. Specifically, we seek to effect a cure by aggressively suppressing HBV replication within liver cells, stimulating and reactivating the body's immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.

OnCore is located at the Pennsylvania Biotechnology Center in Doylestown, Pennsylvania, which is also home to the Hepatitis B Foundation and the Foundation's research center, the Baruch S. Blumberg Institute.

For more information, please visit www.oncorebiopharma.com . To be added to the Company's email list to receive news directly, please send an email to ir@oncorebiopharma.com .

About the Baruch S. Blumberg Institute

The Baruch S. Blumberg Institute, formerly the Institute for Hepatitis and Virus Research, is the nation's leading nonprofit research organization dedicated to hepatitis B and liver cancer. The Baruch S. Blumberg Institute was established in 2003 by the Hepatitis B Foundation to fulfill its research mission of finding a cure for hepatitis B in our lifetime and to conduct discovery research and nurture translational biotechnology in an environment conducive to interaction, collaboration and focus. To learn more, please visit www.blumberginstitute.org .

About the Hepatitis B Foundation

Headquartered in Doylestown, Pa., the Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, please visit www.hepb.org .

Patrick T. Higgins, CEO

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 25

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 142

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 115

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 150

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 81

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 177

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 98

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 115

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 83

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading

Top 5 Most Recently Viewed Articles

New Terminal One Partners with Plaza Premium to Elevate Travel

Updated Category News Views 234

New Terminal One & Plaza Premium Group Collaboration The New Terminal One at JFK International Airport has joined forces with Plaza Premium Group (PPG), a leading name in airport hospitality, to create two state-of-the-art lounges. Together, they aim to transform the travel experience at this vital international hub, covering close to 14,000 square feet and promising...

Continue Reading
Market Update: S&P 500 Fluctuates After Holiday Trading

Updated Category News Views 337

S&P 500 Experiences Mixed Results in Light Trading The recent trading session saw the S&P 500 close on a flat note after a day of ups and downs, all in the backdrop of lower-than-usual trading volumes, a trend typical of the holiday breakout. As of the market close, the S&P 500 had dipped by 0.1%, while the NASDAQ Composite mirrored this decrease. In contrast, the Dow...

Continue Reading
Brand Engagement Network Expands Horizons with Cataneo Acquisition

Updated Category News Views 104

Brand Engagement Network Expands Strategic Capabilities Jackson, Wyo. – brand Engagement Network, Inc. (NASDAQ: BNAI) has recently made headlines by agreeing to acquire a German media technology powerhouse, Cataneo Gmbh. This acquisition not only highlights BEN's commitment to growth but also demonstrates its ambition to transform how brands use AI to engage with their...

Continue Reading
Metagenomi Showcases Advanced Adenine Base Editors for Gene Therapy

Updated Category News Views 195

Introducing Metagenomi's Innovative Adenine Base Editors Metagenomi has unveiled its cutting-edge Adenine Base Editors (ABEs) at a recent event, highlighting their impressive capabilities in genome editing. These novel tools achieved over 95% targetability in gene modification, demonstrating exceptional performance and efficiency. Key Highlights from the Presentation...

Continue Reading
Streamlining IT Procurement: SysAid Launches on AWS Marketplace

Updated Category News Views 49

SysAid Now Accessible via AWS Marketplace SysAid, a leading Enterprise and IT Service Management solution provider, has made an exciting announcement regarding its availability on AWS Marketplace. This curated digital catalog is designed to simplify the process of discovering, procuring, and deploying software solutions. With AWS Marketplace having over 290,000 active...

Continue Reading